Jiangzhong's acquisition of Sanghai Pharmaceuticals and Jisheng Pharmaceuticals' commitment to China Resources is only one step

Jiangzhong's acquisition of Sanghai Pharmaceuticals and Jisheng Pharmaceuticals has reached an agreement, which is getting closer and closer to China Resources.Tonjiang To buy two pharmaceutical companies and reach an agreement
On July 28, Jiangzhong Pharmaceuticals issued an announcement on the signing of a framework agreement for cooperation and progress in major asset restructuring.
announced that on July 26, 2018, Jiangzhong Pharmaceutical Co., Ltd. and Jiangxi Sanghai Group Co., Ltd. signed a "Cooperation Framework Agreement" to reach an agreement on the acquisition of a 51% stake in its wholly-owned subsidiaries, Sanghai Pharmaceuticals and Jisheng Pharmaceuticals.
's acquisition of the two companies comes against the backdrop of China Resources' entry into the main river.China Resources into the main river, more recently
On May 16, Jiang Chinese Medicine issued a "announcement on the progress of the company's actual controlling company in planning major matters." According to the announcement, Jiangxi SASAC and China Resources Pharmaceutical Group Co., Ltd. are in talks to restructure Jiang zhong group strategically, and if the transaction is completed, jiang traditional Chinese medicine's indirect controlling shareholder may be changed to China Resources Pharmaceutical Group Co., Ltd.
restructuring plan includes Jiangzhong Pharmaceuticals' planned acquisition of a controlling stake in China Resources Pharmaceutical Co., Ltd., a subsidiary of China Resources Pharmaceutical Group Co., Ltd., a controlling stake in Jiangxi Nanchang Sanghai Pharmaceutical Co., Ltd., and a controlling stake in Jiangxi Nanchang Jisheng Pharmaceutical Co., Ltd.
the end, China Resources Pharma took a 51% or more stake in Jiang zhong group by buying a portion of Jiang zhong shares and increasing capital to Jiangjiang Group in cash or assets.
reached an agreement with Jiangzhong to acquire Sanghai Pharmaceuticals and Jisheng Pharmaceuticals, a step closer to China Resources.Jiang Traditional Chinese Medicine will soon be included in the "China Resources Map
follow-up to June 2 Jiangsao Pharmaceuticals issued "on the company's actual controller to change the prompt announcement" shows that China Resources Pharmaceutical Holdings intends to increase capital and purchase part of Jiangxi Jiang zhong pharmaceutical (Group) Co., Ltd. shares in the combination of the acquisition of Jiang zhong group not less than 51% of the shares. Jiang Zhong Group is the controlling shareholder of Gongjiang Chinese Medicine, holding 43.03% of the issued shares.Jiang Chinese medicine industry's home base
Jiangjiang in the 2017 annual report, its core resources are presented: two well-known trademarks and a number of excellent marketing team - Jiangjiang Chinese medicine industry in the field of Chinese medicine gastric food market share of about 70%, ranking first in the industry. The market share of Chinese medicine throat tablets is about 25%, ranking 2nd in the industry.
also have two lines of business mature marketing channels. Including more than 100,000 controllable pharmacy terminals, more than 30,000 controllable hyper-terminals;China Resources brand-name strategy
China Resources Pharmaceuticals since 2007, every merger and acquisition are attracting attention. In May 2007, China Resources Pharma integrated DongA Glue, Huayuan Group Pharmaceutical Resources, 39 Pharmaceuticals, and in July 2010, after reorganizing Beijing Pharmaceutical Group, established China Resources PharmaceuticalsPharmaceutical Co., Ltd.,
subsequently completed the merger of China Resources Shuanghe, China Resources Zizhu, China Resources Pharmaceuticals Commercial and Pharmaceutical Research and Development Center, and became a subsidiary of China Resources Pharmaceuticals.
has "three nine" "double crane" "East A" "purple bamboo" "Yu" national well-known brands, now, "Jiang zhong" will also be included. (Seber Blue)